Inventor · disambiguated record
Alan J. Bitonti
Also filed as: BITONTI ALAN · BITONTI ALAN J · BITONTI ALAN R
43 granted patents·24 pending applications·1,366 citations·filing 1988–2024
98Inventor score
Files withBIOVERATIV THERAPEUTICS INC16DYAX CORP7MERRELL DOW PHARMA7MERRELL PHARMA INC7SYNTONIX PHARMACEUTICALS INC7
Top patents by PatentIndex Score
67 records- 0198US7862820B2Immunoglobulin chimeric monomer-dimer hybridsSYNTONIX PHARMACEUTICALS INC·Filed 2006·Granted Jan 4, 2011·120 cites·13 claims
- 0298US7404956B2Immunoglobulin chimeric monomer-dimer hybridsSYNTONIX PHARMACEUTICALS INC·Filed 2004·Granted Jul 29, 2008·301 cites·48 claims
- 0398US7348004B2Immunoglobulin chimeric monomer-dimer hybridsSYNTONIX PHARMACEUTICALS INC·Filed 2005·Granted Mar 25, 2008·218 cites·20 claims
- 0497US7566565B2PC5 as a factor IX propeptide processing enzymeSYNTONIX PHARMACEUTICALS INC·Filed 2007·Granted Jul 28, 2009·44 cites·22 claims
- 0596US8449884B2Clotting factor-fc chimeric proteins to treat hemophiliaRIVERA DANIEL S·Filed 2010·Granted May 28, 2013·65 cites·24 claims
- 0696US8329182B2Immunoglobulin chimeric monomer-dimer hybridsPETERS ROBERT T·Filed 2010·Granted Dec 11, 2012·82 cites·38 claims
- 0795US9260520B2Antibodies to FeRn and uses thereofDYAX CORP·Filed 2014·Granted Feb 16, 2016·18 cites·6 claims
- 0894US11266720B2Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Mar 8, 2022·6 cites·64 claims
- 0994US8932830B2Immunoglobulin chimeric monomer-dimer hybridsBIOGEN IDEC HEMOPHILIA INC·Filed 2012·Granted Jan 13, 2015·25 cites·27 claims
- 1094US8815246B2Fc receptor binding proteinsTENHOOR CHRISTOPHER·Filed 2012·Granted Aug 26, 2014·18 cites·12 claims
- 1194US8273351B2Fc receptor binding proteinsTENHOOR CHRISTOPHER·Filed 2009·Granted Sep 25, 2012·20 cites·6 claims
- 1294US8021880B2PC5 as a factor IX propeptide processing enzymeSYNTONIX PHARMACEUTICALS INC·Filed 2010·Granted Sep 20, 2011·17 cites·23 claims
- 1393US10881742B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Jan 5, 2021·5 cites·26 claims
- 1493US9050318B2Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereofDUMONT JENNIFER A·Filed 2010·Granted Jun 9, 2015·28 cites·31 claims
- 1593US8815250B2Clotting factor-Fc chimeric proteins to treat hemophiliaBIOGEN IDEC HEMOPHILIA INC·Filed 2013·Granted Aug 26, 2014·19 cites·24 claims
- 1692US7795400B2PC5 as a factor IX propeptide processing enzymeSYNTONIX PHARMACEUTICALS INC·Filed 2009·Granted Sep 14, 2010·10 cites·15 claims
- 1791US10023628B2Cell line expressing single chain factor VIII polypeptides and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Jul 17, 2018·6 cites·17 claims
- 1890US9725496B1Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Aug 8, 2017·4 cites·27 claims
- 1990US9241978B2Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereofBIOGEN HEMOPHILIA INC·Filed 2013·Granted Jan 26, 2016·15 cites·21 claims
- 2089US6413974B16,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purinesAVENTIS PHARMA INC·Filed 1999·Granted Jul 2, 2002·94 cites·27 claims
- 2188US12186375B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Jan 7, 2025·1 cites·19 claims
- 2287US11168125B2Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Nov 9, 2021·1 cites·10 claims
- 2386US6479487B16, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purinesAVENTIS PHARMA INC·Filed 1999·Granted Nov 12, 2002·78 cites·193 claims
- 2486US2025195620A1Factor viii chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2584US2023023927A1Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2682US4935449AN-2,3-butadienyl tri- and tetraaminoalkane derivativesMERRELL DOW PHARMA·Filed 1988·Granted Jun 19, 1990·28 cites·9 claims
- 2782US2022010000A1Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2877US2022265780A1Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2976US2021348150A1Clotting factor-fc chimeric proteins to treat hemophiliaBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3075US2021355473A1Chimeric clotting factorsBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3172US5525633ATriaryl-ethylene derivativesMERRELL DOW PHARMA·Filed 1994·Granted Jun 11, 1996·12 cites·15 claims
- 3270US11401322B2Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Aug 2, 2022·0 cites·25 claims
- 3367US5593664AAntiangiogenic oligomersMERRELL PHARMA INC·Filed 1993·Granted Jan 14, 1997·21 cites·18 claims
- 3465US2016222110A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 3565US2013045218A1Fc receptor binding proteinsSYNTONIX PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 3664US2015044207A1Clotting Factor-Fc Chimeric Proteins to Treat HemophiliaBIOGEN IDEC HEMOPHILIA INC·Filed 2014·Application pending·0 cites
- 3764US2018237762A1Clotting factor-fc chimeric proteins to treat hemophiliaBIOVERATIV THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3863US10968442B2Chimeric clotting factorsBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Apr 6, 2021·0 cites·23 claims
- 3963US2016194397A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 4063US2016222111A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 4163US2016222112A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 4263US2016222109A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 4363US2016222108A1Fc receptor binding proteinsDYAX CORP·Filed 2015·Application pending·0 cites
- 4462US5684004ATriaryl-ethylene derivativesMERRELL PHARMA INC·Filed 1995·Granted Nov 4, 1997·9 cites·12 claims
- 4562US5134168APhenoxy and phenylthio, amino substituted benzocycloalkane derivatives in the treatment and prevention of drug-resistant protozoal infectionsMERRELL DOW PHARMA·Filed 1991·Granted Jul 28, 1992·16 cites·13 claims
- 4661US6642231B26,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purinesAVENTIS PHARMA INC·Filed 2002·Granted Nov 4, 2003·1 cites·21 claims
- 4761US5607925ATreatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosidesMERRELL PHARMA INC·Filed 1994·Granted Mar 4, 1997·12 cites·6 claims
- 4860US5693674AMethod of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosisHOECHST MARION ROUSSEL INC·Filed 1996·Granted Dec 2, 1997·16 cites·16 claims
- 4959US2005147618A1Clotting factor-Fc chimeric proteins to treat hemophiliaFiled 2004·Application pending·0 cites
- 5056US5753714APolyamine derivativesMERRELL PHARMA INC·Filed 1994·Granted May 19, 1998·5 cites·31 claims
Showing the top 50 of 67 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Alan J. Bitonti files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →